不同途径应用血小板GPⅡb Ⅲa受体拮抗剂的进展（国外英文资料）.docVIP

不同途径应用血小板GPⅡb Ⅲa受体拮抗剂的进展 Advances in the application of platelet GP II, b/ III and a receptor antagonists in different ways Beijing An Zhen Hospital affiliated to Capital Medical University: Yan Hongbing Keywords: acute coronary syndrome, PCI, platelet GP II, b/ III, a receptor antagonists Acute coronary syndrome (ACS) refers to a group of clinical symptoms caused by acute myocardial ischemia, mainly by the unstable plaque rupture secondary to coronary artery thrombosis caused by in China has become a common cardiovascular disease. Emergency percutaneous coronary intervention (PCI), especially by experienced operators, can quickly and effectively opening of infarct related artery (IRA), the early myocardial reperfusion and reduced mortality in patients with acute myocardial infarction (AMI) is the preferred treatment strategies. However, even in todays era of interventional therapy, 5 to 50% of patients still fail to achieve optimal reperfusion after emergency PCI surgery, i.e., no reflow is the independent risk factor for long-term prognosis. Platelet GP II, b/ III, and a receptor antagonists block the eventual common pathway of platelet aggregation, and have been shown to reduce the occurrence of no reflow after PCI. STEMI ACC/AHA will guide the treatment of perioperative intravenous platelet GP II b/ III a receptor antagonist as a class II indication. However, it can not be ignored that the incidence of bleeding is as high as 6%, and the rate of severe bleeding can reach 4%. The recent case reports and small studies show that compared with the intravenous route of administration, the coronary artery in the local application of GP II b/ III a receptor antagonist in emergent PCI shows short term effect of similar or better than intravenous, and lower incidence of bleeding. It is suggested that the use of GP II, b/ III, and a receptor antagonists in coronary arteries is likely to be a new approach and strategy for perioperative antiplatelet therapy in patients with